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Abstract 
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of 
reproductive age. PCOS is associated with multiple co-morbidities including, obesity, insulin 
resistance and type 2 diabetes, as well as mood disorders and impaired quality of life (QoL). 
Obstructive sleep apnoea (OSA) is also a common medical condition that is often 
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undiagnosed, particularly in women. OSA is associated with a similar spectrum of 
comorbidities to that observed in PCOS, including manifestations of the metabolic syndrome 
and impaired QoL, whilst obesity frequently constitutes a common denominator in the 
pathophysiology of both OSA and PCOS. Hence, it is not surprising that OSA and PCOS 
may co-exist in women of reproductive age, and the current clinical guidelines on the 
management of PCOS recommend screening for OSA symptoms in overweight/obese women 
with PCOS. In this review, we examine the relationship between OSA and PCOS and explore 
the potential underlying mechanisms that link these two conditions.  
 
1. Introduction 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of 
reproductive age with a prevalence of 6–15% (3, 4). PCOS is associated with obesity, 
subfertility, insulin resistance (IR) and type 2 diabetes (T2DM), depression and impaired 
quality of life (QoL) (1, 5). However, despite its high prevalence and significant co-
morbidities, our understanding of its underlying pathophysiology remains poor; with limited 
treatment options available to manage this lifelong disorder in everyday clinical practice. 
Hence, there is a need to improve the understanding of the pathogenesis of PCOS and the 
spectrum of factors that might contribute to the clinical manifestations and comorbidities of 
this very common condition. 
Obstructive sleep apnoea (OSA) is also an obesity-related disorder. OSA prevalence in the 
general population is estimated at 17–26% in men and 9–28% in women, but this difference 
varies depending on the definition and methods used to diagnose OSA (6). OSA is 
characterised by recurrent episodes of partial (hypopnoea) or complete (apnoea) upper airway 
obstructions associated with recurrent oxygen desaturations and cyclical changes in heart 
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rate, blood pressure, intrathoracic pressure and sympathetic activity (7). In addition, OSA 
results in changes in the sleep architecture, including loss of deep sleep (stages 3 and 4) 
and/or of REM sleep (7).  
Patients with OSA may present with nocturnal symptoms, including snoring, witnessed 
apnoea episodes, choking or gasping, insomnia, nocturia, enuresis, frequent arousals, 
diaphoresis, and impotence (8). In addition, common daytime OSA symptoms may include 
excessive daytime sleepiness, fatigue, memory impairment, morning headaches, and 
depression (8). Prompt diagnosis and treatment of OSA is highly important in clinical 
practice, since undiagnosed/untreated OSA is associated with increased risk of hypertension, 
cardiovascular disease, mortality, IR and T2DM, road traffic accidents, depression and 
impaired QoL (8, 9) . Continuous positive airway pressure (CPAP) therapy, combined with 
weight loss for overweight/obese patients, is the treatment of choice for symptomatic OSA 
(10). 
Despite the high prevalence of OSA in the general population, this condition is generally 
under-recognised and frequently remains undiagnosed in everyday clinical practice, 
particularly in women who may not present with typical OSA symptoms (11). As obesity is a 
common risk factor, it is not surprising that OSA and PCOS might co-exist. The association 
between PCOS and OSA has also been recognised in the latest guidelines by the European 
and the US Endocrine Societies (Box 1) (1, 2). However, these guidelines acknowledge the 
limited evidence behind their recommendations that is largely based on limited, ‘weak’, or 
‘low quality’ data. This highlights the need for further research to better understand the 
relationship between PCOS and OSA. In addition, the implications of OSA in women with 
PCOS are not clear, though important as both conditions are associated with overlapping 
comorbidities, and OSA is associated with essential factors that may contribute to the burden 
of PCOS (e.g. to IR, increased inflammation, and oxidative stress) (6, 12). In this article we 
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present a concise review of key studies that examined the relationship between OSA and 
PCOS, and we explore the potential mechanisms linking both conditions. 
 
 
 
2. Methodology 
We conducted a narrative review of the relevant literature. In this context, we searched 
PubMed using the terms ‘(PCOS OR polycystic ovary syndrome) AND (OSA OR obstructive 
sleep apnoea OR obstructive sleep apnea)’. Clinical studies and review articles examining the 
presence of OSA in women with PCOS were obtained, reviewed, and their results were 
critically appraised. We also hand-searched references from relevant papers and review 
articles. 
3. Epidemiology 
3.1 PCOS prevalence in OSA 
PCOS has a prevalence of 6–15% in women of reproductive age (3); however, the reported 
prevalence rates vary depending on the populations studied and the applied PCOS diagnostic 
criteria. The prevalence of PCOS in women with OSA remains unknown. 
Box 1. Clinical guidelines/recommendations on screening women with PCOS for OSA. 
1. Endocrine Society, 2013 (1): 
We suggest screening overweight/obese adolescents and women with PCOS for symptoms 
suggestive of OSA and, when identified, obtaining a definitive diagnosis using 
polysomnography. If OSA is diagnosed, patients should be referred for institution of 
appropriate treatment. 
2. European Society of Endocrinology, 2014 (2): 
It seems wise at this moment to screen sleep disorders by clinical questionnaires in obese 
women with PCOS. In the case of clinical suspicion resulting from these questionnaires, 
patients should be referred to a centre of sleep disorders for polysomnography and further 
evaluation. 
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3.2 OSA prevalence in PCOS 
The prevalence of OSA in the general population varies considerably between studies, mainly 
due to differences in the populations studied, study designs, and the methods and criteria used 
to diagnose OSA (8). The prevalence from three well-conducted studies with similar designs 
from the USA (Wisconsin and Pennsylvania), and Spain showed an OSA prevalence of  9–
28% in women, with 2–7% for moderate to severe OSA (13).  
To date, a limited number of studies have examined the prevalence of OSA in women with 
PCOS with the majority of these being conducted in the USA. Based on the existing 
published studies (14-22) (Table 1), the reported prevalence of OSA in women with PCOS 
ranges from 0% to 69% (median: 55.8%; mean: 39.8%). This large variability and wide range 
in the reported prevalence may be attributed to a combination of reasons, including 
application of different cut-off points and methods to diagnose OSA, the small size of the 
studied cohorts, and potential selection bias by recruitment of study participants from 
specialised clinics. As expected, the available data suggest that OSA risk in women with 
PCOS is increased with age and obesity. While the only published study that examined the 
presence OSA in lean women with PCOS showed no evidence of the condition (18), the 
small number of study participants (n=18) precludes generalisability or drawing firm 
conclusions from these data. The reported prevalence and potential links between PCOS and 
OSA in adolescents are even more controversial, with one study showing a prevalence of 
16/28 (57%) (20) and another showing 0/22 (0%) prevalence (19). Based on the available 
data on the prevalence and natural history of these two conditions, it is probable that PCOS 
precedes the development of OSA; however, it cannot be excluded that OSA may precede the 
clinical presentation of PCOS in some women, worsening the PCOS-related 
symptomatology. Observational long-term studies are needed to accurately assess the 
incidence of OSA in women with PCOS and vice versa. 
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4. Proposed mechanisms linking OSA to PCOS and its comorbidities 
Depending on ethnicity and geography, 30–88% of women with PCOS are overweight or 
obese (23). Obesity may contribute to the development of PCOS through increased android 
(central) type adiposity and IR (24); lipotoxicity (25); and increased 5α-reductase activity 
(23). Obesity is also a major risk factor for OSA (8). The mechanisms that link obesity to 
OSA are multifactorial (8, 26). Weight gain can alter normal upper airway mechanics during 
sleep by various mechanisms, such as increased parapharyngeal fat deposition resulting in a 
smaller upper airway; altering the neural compensatory mechanisms that maintain airway 
patency; reducing the functional residual capacity with a resultant decrease in the stabilising 
caudal traction on the upper airway; reducing lung volume due to increased abdominal fat; 
increasing breathing workload due to increased chest wall thickness; and affecting the 
chemosensitivity to O2 and CO2 which reduces the ventilatory drive (8, 26). Subsequently, 
obesity is a key factor that predisposes to both PCOS and OSA. However, other shared 
features between PCOS and OSA may also play an important mechanistic role in the 
development/interaction between these two common conditions. 
4.1 Sex Hormones 
An increase in circulating androgens of ovarian origin is one of the main features of PCOS 
and is present in both ovulatory and anovulatory women. Androgens cause many of the 
clinical features of PCOS (e.g. hirsutism, acne and alopecia); contribute to anovulation by 
promoting ovarian early follicular growth and subsequently disrupt follicular development 
and dominant follicle selection (27); and exacerbate IR. Anovulation will result in lower 
progesterone levels. Hyperandrogensim and low progesterone levels may play a role in the 
pathogenesis of OSA by increasing upper airway collapsibility, and/or impairing the 
sensitivity and responsiveness of the ventilatory chemoreceptors (28). However, the effect of 
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hyperandrogenism on OSA risk in women with PCOS is probably small, as androgen levels 
are relatively low compared to men. Sleep, on the other hand, appears to have a significant 
effect on the female hormone production (29). Indeed, sleep deprivation and/or interruption, 
and sleep disordered breathing have been suggested to influence gonadotropin releasing 
hormone (GnRH), follicular stimulating hormone (FSH) and luteinising hormone (LH) 
pulsatility and may cause menstrual disturbances (30, 31). Subsequently, OSA may alter sex 
hormones production and contribute to the development or worsening of the clinical features 
of PCOS. 
4.2 Insulin resistance 
IR is seen in more than 50% of women with PCOS, independent of obesity (32). Insulin may 
act directly on the ovaries to enhance androgen production (33); reduce SHBG production 
from the liver with subsequent increase in bioavailable testosterone; and cause the premature 
arrest of follicle growth and anovulation (34). Most studies also suggest an association 
between OSA and IR (8); and studies in healthy lean men found OSA to be associated with 
IR even in the absence of obesity (35). In addition, in a cohort study, OSA, apnoea/hypopnea 
index (AHI), oxygen desaturation index (ODI), and minimal oxygen saturations were 
independently associated with IR development over an 11-year follow-up period after 
adjustment for age, baseline BMI, BMI change over follow-up, hypertension, and CPAP 
treatment (36). Two recent meta-analyses showed that CPAP treatment was associated with a 
reduction in the homeostasis model assessment of insulin resistance (HOMA-IR) (37, 38), 
although this benefit may occur only in those using CPAP >4 hours per night (39). 
Subsequently, it is plausible that OSA, through IR, may contribute to the development of a 
more severe PCOS phenotype in women affected by both conditions; or to a de novo 
presentation of PCOS in genetically/metabolically predisposed women. 
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4.3 Oxidative stress 
In a recent systematic review and meta-analysis, PCOS was associated with increased levels 
of oxidative stress, independent of age and BMI (40). Oxidative stress may play a role in the 
pathogenesis of PCOS by exacerbating IR (41); causing hyperandrogenism (41); and 
contributing to infertility (42). Many studies suggest that OSA is a cause of oxidative stress 
(8). Recurrent hypoxia and mitochondrial dysfunction in OSA result in the formation of 
reactive oxygen species (ROS) which leads to cellular and DNA damage and oxidative stress 
(43). Subsequently, OSA may complicate the clinical picture in PCOS by promoting 
oxidative stress.  
4.4 Endothelial dysfunction 
Women with PCOS have been found to have lower flow-mediated dilatation (FMD) 
compared to age- and weight-matched controls (44). Obesity, IR, oxidative stress, advanced 
glycation end products (AGE) and inflammation are believed to play a role in the 
pathogenesis of endothelial dysfunction in PCOS (45). OSA is also associated with 
endothelial dysfunction and the underlying mechanisms are likely related to ischemia-
reperfusion injury (46). Repetitive episodes of re-oxygenation after hypoxemia in patients 
with OSA result in increased production of AGE and ROS (43); altered protein kinase C 
signaling; decreased endothelial nitric oxide synthase (47); increased endothelin-1 levels and 
inflammation (48). Notably, CPAP treatment was found to increase FMD in patients with 
OSA (49). 
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4.5 Sympathetic activity 
Sympathetic activity is increased in obesity and is associated with visceral adiposity (50); 
high leptin levels (51) and IR (52) are thought to play a role in its pathogenesis. However, 
increased sympathetic activity may further exacerbate IR and creates a vicious cycle (52). 
Women with PCOS have evidence of increased sympathetic activity (52), even in the absence 
of obesity (53). Sympathetic activity may contribute to the pathogenesis of PCOS through 
increased IR, altered ovarian function and the development PCO morphology (52). OSA is 
also associated with an increase in sympathetic activity independent of body weight (54). It is 
likely that both the recurrent hypoxia (55) and recurrent arousals (56) contribute to the 
activation of the sympathetic nervous system (SNS). Moreover, treatment with CPAP is 
associated with a reduction in sympathetic activity (57).  
4.6 Summary of the proposed mechanisms linking OSA and PCOS 
OSA and PCOS are both associated with comorbidities including obesity, IR, oxidative 
stress, endothelial dysfunction, sympathetic hyperactivity, and hormonal disturbances that 
could potentially contribute to the pathophysiology and development of either condition. It is 
thus plausible that the relationship between OSA and PCOS is bidirectional, where PCOS 
contributes to the development of OSA, and vice versa, OSA contributes to the clinical 
presentation of PCOS, worsening its symptomatology and creating a vicious cycle between 
the two conditions. An illustration of the possible pathophysiological links between OSA and 
PCOS and their clinical consequences is provided in Figure 1. 
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5. The impact of OSA in women with PCOS 
5.1 Review of published studies 
A limited number of studies have examined the effect(s) of OSA in women with PCOS and 
their findings are summarised in Table 1. 
In the study by Vgontzas et al. (15), women with PCOS and sleep disordered breathing (SDB 
was defined as either OSA or upper airway resistance syndrome; n=9) were heavier (BMI 
45.7±2.6 vs. 37.2±1.1 kg/m
2
, P<0.003), and had higher fasting insulin (306.5±52.4 vs. 
176.1±18.5 pmol/L, P<0.01) and lower glucose-to-insulin ratio (0.02±0.006 vs. 0.04±0.003, 
P<0.05) compared to women with PCOS without SDB (n=44). Logistic regression analysis of 
the study data showed that insulin levels and glucose-to-insulin ratio had a stronger 
association with SDB than age, BMI, or testosterone levels. However, the difference in BMI 
between the two groups in this study was rather high (8.5 kg/m
2
), and despite statistical 
adjustment, it is difficult to completely rule out an effect of obesity on the metabolic 
differences between the two groups. 
Similarly, in the study by Tasali et al. (17), women with PCOS and OSA (n=29) were older 
(age 31.6±1.0 vs. 27.3±0.7 years; P=0.002), had a higher BMI (42.2±1.1 vs. 35.3±1.4 kg/m
2
 ; 
P<0.001), and were more insulin resistant (HOMA-IR 5.7±0.4 vs. 3.5±0.4, P=0.006) than 
women with PCOS without OSA (n=23). After controlling for age, BMI, and ethnicity, AHI 
was a highly significant predictor of the fasting concentrations of glucose and insulin, as well 
as of the 2-h glucose concentration (after an oral glucose tolerance test) and HOMA-IR. The 
data of this study also suggest that the degree of sleep fragmentation, rather than the severity 
of hypoxia, may be related to the severity of IR and glucose intolerance in women with 
PCOS. As such, the authors further concluded that women with PCOS and OSA represent a 
metabolically different, ‘higher risk’ population compared to women with PCOS without 
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OSA. However, this conclusion should be taken with caution considering the small study 
sample size, and the relatively large difference in BMI (7.1 kg/m
2
) between women with and 
without OSA in this study. 
Notably, Tasali et al. have also conducted a relevant short-term interventional study (58) in 
19 obese women with PCOS and OSA (age ± SEM: 31.2±1.2 years; BMI: 46.4±2.4 kg/m
2
). 
These women were treated with CPAP for 8 weeks, exhibiting subsequent improvement in 
insulin sensitivity (relative increase of nearly 7%), and reduction in diastolic blood pressure 
(DBP; approximately 2.3 mmHg). In addition, day-time and night-time norepinephrine levels 
also reduced after CPAP therapy. However, this study lacked a control group, and only a ‘per 
protocol’ analysis was performed including just 9 study participants, with the data from 
another 10 study patients being excluded from the analysis due to lack of adequate CPAP 
treatment compliance (average use of CPAP <4 hours per night). Of note, whether the 
reported post-treatment changes in IR and blood pressure observed in this study may 
translate/result into meaningful clinical outcomes remains to be studied.  
In another study by Tock et al. (21), women with PCOS and OSA (n=12) had higher BMI 
(37.8±4.8 vs. 30.67±7.7 kg/m
2
, P=0.006); waist circumference (114.4±12.0 vs. 98.1±19.9 cm, 
P=0.013); waist-to-hip ratio (1.0±0.1 vs. 0.9±0.1, P=0.029); free testosterone (1.9±1.3 vs. 
1.1±0.8 ng/dL, P=0.014); HOMA-IR (4.4±3.2 vs. 2.3±1.4, P=0.009); total cholesterol 
(205.0±28.7 vs. 172.3±35.8 mg/dL, P=0.009); low density lipoprotein-cholesterol (LDL,  
128.6±21.6 vs. 98.9±29.6, P=0.004); and higher prevalence of non-alcoholic fatty liver 
disease (NAFLD, 83.3% vs. 26.9%, P<0.001) compared to those without OSA (n=26). After 
adjusting for obesity in multivariate logistic regression analysis, raised serum free 
testosterone levels ≥1.07 ng/dL increased the risk of OSA in women with PCOS by 8.2 fold. 
Accordingly, the authors concluded that hyperandrogenism may be a predisposing factor for 
OSA in PCOS. However, a limitation of this study is the fact that testosterone was measured 
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by immunoassay rather than by tandem mass spectrometry. In a subsequent multiple logistic 
regression analysis, with OSA (AHI ≥5), IR (HOMA-IR ≥2.7), and obesity (BMI ≥30 kg/m2) 
considered as independent variables and NAFLD as the dependent variable, only OSA was an 
independent predictor of the presence of NAFLD. The presence of OSA increased the chance 
of NAFLD 7.6 fold in woman with PCOS. As such, the authors concluded that OSA is a 
predictor of NAFLD along with, but independent of, obesity and IR. 
In a recent study by Chatterjee et al. (22), women with PCOS and SDB (n=33) had higher 
BMI (29.8±3.4 vs. 24.36±2.29 kg/m
2
, P<0.001), waist circumference (95.58±6.47 vs. 
85.12±4.34, P<0.001), systolic BP (SBP, 129.27±10.93 vs. 119.18±8.03 mmHg, P=0.002), 
diastolic BP (78.61±9.07 vs. 73.53±6.22 mmHg, P=0.044), and hirsutism (Ferriman–Gallwey 
score 9.82±2.78 vs. 8.00±2.5, P=0.028) compared to women with PCOS without SDB 
(n=17). Interestingly, in a logistic regression analysis which adjusted for BMI, only the 
associations between fasting plasma glucose and diastolic BP with SDB remained significant.  
Finally, in the study by Nandalike et al. (20), adolescent girls with PCOS and OSA (n=16) 
had higher prevalence of the metabolic syndrome (56.3% vs. 8.3%, P=0.03); higher HOMA-
IR >4 (81.3% vs. 41.6%, P=0.03), systolic BP (128.4±12.8 vs. 115.6±11.4 mmHg, P=0.009), 
triglycerides (149.7±87.7 vs. 93.3±25.8 mg/dl, P=0.03), and lower high density lipoprotein 
(HDL, 38.6±8.7 vs. 49±10.9 mg/dl, P=0.01) compared to girls with PCOS without OSA 
(n=12). 
5.2 Summary of the literature 
It seems plausible that OSA is associated with the severity of the PCOS phenotype, 
particularly in overweight/obese and insulin resistant women with PCOS. However, it is 
difficult to draw firm conclusions from the studies conducted so far since significant 
variables (e.g. abdominal adiposity and ethnicity) have often not been accounted for in the 
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presented analyses. In addition, while the association between OSA and increased insulin 
resistance in women with PCOS seems to be a common theme, the relationship between OSA 
and hyperandrogenism is more controversial and require further evaluation. While the US 
and European Endocrine societies’ guidelines consider the presence of OSA as a 
cardiovascular risk factor in women with PCOS (1, 2), there is lack of data on the exact 
relationship between OSA and important clinical outcomes in women with PCOS (e.g. on 
T2DM risk, cardiovascular risk, subfertility, depression, and impaired QoL). Subsequently, 
well conducted observational studies are needed to examine the effects of OSA in women 
with PCOS. Interventional studies are also required in women with PCOS and OSA. The 
existing short-term, pilot, interventional study in such patients suggests that CPAP therapy 
may significantly improve insulin sensitivity and reduce blood pressure. However, it remains 
unclear whether this can translate into long-term meaningful clinical outcomes.  
 
6. Conclusions 
OSA appears to be common in obese women with PCOS. There is a lack of high-quality 
evidence regarding the clinical benefit or the cost-effectiveness of the current Endocrine 
Society clinical practice guidelines which suggest screening all overweight/obese adolescents 
and women with PCOS for symptoms suggestive of OSA. While it is probable that PCOS 
precedes and contributes to the development of OSA, it is also plausible that OSA may 
contribute to the presentation and worsen the clinical manifestations of PCOS. Both 
conditions are associated with significant comorbidities in women (e.g. depression, 
unexplained fatigue, hypertension, dyslipidaemia, IR and impaired glucose tolerance), and 
may progress undiagnosed for prolonged periods. In order to inform clinical practice and 
support evidence-based guidelines, further clinical research is needed, including prospective 
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cohort studies in obese and non-obese women with PCOS, to study in detail the relationship 
between these two important and prevalent conditions. 
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Study Notes n OSA Women with PCOS and OSA compared to women with PCOS without OSA 
   Diagnosis % 
Weight 
or BMI 
WC or 
WHR 
IR 
Hyperandro-
genism 
BP FPG IGT MS 
Vgontzas et al. 
2001; (15) 
USA 53 
AHI ≥10 +  
symptoms 
11–17% ↑ NA Insulin ↑* FT and TT ↔ NA ↔ NA NA 
Fogel et al. 
2001; (14) 
USA 18 AHI >10 66.8% NA ↑ NA NA NA NA NA NA 
Gopal et al. 
2002; (16) 
USA 23 
RDI ≥5 + 
symptoms 
69.6% ↔ NA NA NA NA NA NA NA 
Tasali et al. 
2008; (17) 
USA 52 AHI ≥5 55.8% ↑ NA HOMA-IR ↑* FT and TT ↔ NA ↔ ↑ NA 
Yang et al. 
2009; (18) 
Taiwan,  
lean women 
18 AHI ≥ 5 0%         
De Sousa et al. 
2010; (19) 
Germany, 
adolescents 
22 Not stated 0%         
Nandalike et 
al. 2012; (20) 
USA, 
adolescents, 
retrospective 
28 
AHI >5 or  
apnoea index >1 
57.2% ↔ NA HOMA-IR ↑ FT and TT ↔ ↑ ↔ NA ↑ 
Tock et al. 
2014; (21) 
Brazil 38 AHI ≥5 31.6% ↑ ↑ HOMA-IR ↑ FT ↑* NA ↔ ↑ NA 
Chatterjee et 
al. 2014; (22) 
India 50 
RDI ≥5 + 
symptoms or 
RDI >15 
66% ↑ ↑ HOMA-IR ↔ FT ↔ ↑ ↑* NA ↑ 
Table 1 Differences between women with PCOS and OSA compared to women with PCOS only. n, number of participants; OSA, obstructive sleep 
apnoea; PCOS, polycystic ovary syndrome; AHI, apnoea/hypopnea index; RDI, respiratory distress index; BMI, body mass index; WC, waist circumference; 
WHR, waist-to-hip-ratio; IR, insulin resistance; HOMA-IR, homeostatic model assessment of insulin resistance; FT, Free testosterone; TT, total testosterone; 
BP, blood pressure; FPG, fasting plasma glucose; IGT, impaired glucose tolerance; MS, metabolic syndrome; ↑ statistically significant increase; NA, not 
available; ↔ equal; *adjusted for weight. 
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Figure 1. Possible mechanisms linking common shared features between Obstructive 
Sleep Apnoea (OSA) and Polycystic Ovary Syndrome (PCOS) with their clinical 
consequences. 
 
